Zydus Cadila gets USFDA approval for trial of DESIDUSTAT to Chemotherapy Induced Anaemia (CIA)

DESIDUSTAT

What is Desidustat?

                                          Desidustat is an Investigational New Drug (IND) for the treatment of anaemia. It is a novel drug and is currently undergoing Phase III clinical trial for treating anaemia in chronic kidney disease patients. and also phase II studies for management of COVID 19 patients.

    

                                            Zydus Cadila chairman Pankaj R patel said that CIA is a serious unmet medical need and there is a need for novel therapies to address this condition. 

                                               Desidustat has been specifically designed to improve the haemoglobin and reduce hepcidin (it is a regulator of iron metabolism and it inhibits the iron transport by binding to the iron channel so that the designing of Desidustat is to reduce the hepcidin)

https://smartpharmainfo.blogspot.com

• https://smartpharmainfo.blogspot.com/2020/07/clinical-trial-of-covid-19-covaxin.html

• https://smartpharmainfo.blogspot.com/2020/07/new-protein-based-treatment-of-covid-19.html 

• https://smartpharmainfo.blogspot.com/2020/07/is-heparin-could-block-covid-19-viral.html